Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi XDC, an ADC/Bioconjugates CRDMO, Stages $500 Million IPO

publication date: Nov 7, 2023

WuXi XDC, a China CRDMO that offers drug development and manufacturing for antibody drug conjugates (ADCs) and other novel bioconjugates, is conducting a $500 million Hong Kong IPO. A member of the WuXi AppTec empire, WuXi XDC is 60% owned by WuXi Biologics while WuXi AppTec, the parent, owns the remaining 40%. The IPO comes at a time when ADCs and bioconjugates are hot, the current favorites of many drug companies looking for the best cancer therapies. The company says it will use the funds to expand its manufacturing capacity and fund possible acquisitions. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here